IRF9 抗体 (full length)
Our Local Distributor
北京 101111
Quick Overview for IRF9 抗体 (full length) (ABIN7878453)
抗原
See all IRF9 抗体适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
抗原表位
- full length
-
原理
- IRF9 Antibody / Interferon regulatory factor 9
-
纯化方法
- Protein A/G affinity
-
免疫原
- Recombinant full-length human IRF9 protein was used as the immunogen for the IRF9 antibody.
-
亚型
- IgG2a
-
-
-
-
应用备注
- Optimal dilution of the IRF9 antibody should be determined by the researcher.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 0.2 mg/mL
-
缓冲液
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- -20 °C
-
储存方法
- Aliquot the IRF9 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- IRF9 (Interferon Regulatory Factor 9 (IRF9))
-
别名
- IRF9
-
背景
- Transcription regulatory factor that mediates signaling by type I IFNs (IFN-alpha and IFN-beta). Following type I IFN binding to cell surface receptors, Jak kinases (TYK2 and JAK1) are activated, leading to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize, associate with IRF9/ISGF3G to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of interferon stimulated genes, which drive the cell in an antiviral state.
-
UniProt
- Q00978
-
途径
- JAK/STAT Signaling, Interferon-gamma Pathway, Hepatitis C
抗原
-